Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load

Hepatology

Volumn 58, Issue 2, 2013, Pages 505-513

  Gordon, Stuart C ^a   Krastev, Zahary ^b   Horban, Andrzej ^c   Petersen, Jörg ^d   Sperl, Jan ^e   Dinh, Phillip ^f   Martins, Eduardo B ^f   Yee, Leland J ^f   Flaherty, John F ^f   Kitrinos, Kathryn M ^f   Rustgi, Vinod K ^g   Marcellin, Patrick ^h  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^f GILEAD SCIENCES   (United States)

^g Metropolitan Liver Diseases   (United States)

^h BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE DOSAGE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEROCONVERSION; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

ADENINE; ADULT; ANTIVIRAL AGENTS; DEOXYCYTIDINE; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PHOSPHOROUS ACIDS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84881030204     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26277     Document Type: Article

References (16)

1. Chen C-F, Lee W-C, Yang H-I, Chang H-C, Jen C-L, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011;141:1240-1248, 1248.e1-2.
2. Iloeje UH, Yang H-I, Su J, Jen C-L, You S-L, Chen C-J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
3. Chen C-J, Yang H-I, Su J, Jen C-L, You S-L, Lu S-N, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
4. Buster EHCJ, Hansen BE, Lau GKK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-2009.
5. Cooksley G, Manns M, Lau GKK, Liaw Y-F, Marcellin P, Chow C. Effect of genotype and other baseline factors on response to peginterferon alfa-2a (40 kDa) (Pegasys) in HBeAg-positive chronic hepatitis B: results from a large, randomised study. J Hepatol 2005;42(Suppl 2):30-31.
6. Bonino F, Marcellin P, Lau GKK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007;56:699-705.
7. Zoutendijk R, Reijnders JGP, Brown A, Zoulim F, Mutimer D, Deterding K, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology 2011;54:443-451.
8. Yuen M-F, Seto W-K, Fung J, Wong DK-H, Yuen JC-H, Lai C-L. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011;106:1264-1271.
9. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
10. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2012;pii:S0140-6736(12)61425-1. doi: 10.1016/S0140-6736 (12)61425-1. [Epub ahead of print].
11. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763-773.
12. Zhu Y, Curtis M, Borroto-Esoda K. HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays. J Virol Methods 2011;173:340-346.
13. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-1869.
14. Yuen M-F, Lai C-L. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 2011;26(Suppl 1):138-143.
15. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 2012;143:619-629.e1.
16. Wu I-C, Lai C-L, Han S-HB, Han K-H, Gordon SC, Chao Y-C, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010;51:1185-1189.